Original Article
Copyright ©2010 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 21, 2010; 16(35): 4400-4409
Published online Sep 21, 2010. doi: 10.3748/wjg.v16.i35.4400
Table 5 Reasons for discontinuation of pegylated interferon plus ribavirin treatment by hepatitis C virus genotype 2 patients
Group C (age < 65 yr)
Group D (age65 yr)
Total
Male (n = 124)Female (n = 128)Male (n = 28)Female (n = 33)
Discontinued number18154441
Adverse effects6113323
General fatigue13105
Depression02002
Appetite loss00000
Rash21025
Encephalopathy00011
Neutropenia02002
Anemia00202
Thrombocytopenia20002
Elevation of ALT00000
Hyperthyroidism01001
Hypothyroidism01001
Retinopathy00000
Interstitial pneumonia00000
Pulmonary disease(others)00000
Psychoneurotic disorder00000
Nervous disease111002
Autoimmune disease00000
Metabolic disease00000
Digestive disorder00000
Hepatocellular carcinoma00000
Malignancy (extra-liver)10001
No effect of treatment10001
Economic problem00000
Others21041116